SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies gains on securing GMP Compliance for Goa plant

06 Feb 2014 Evaluate

Indoco Remedies is currently trading at Rs. 123.45, up by 0.55 points or 0.45 % from its previous closing of Rs. 122.90 on the BSE.

The scrip opened at Rs. 122.90 and has touched a high and low of Rs. 123.65 and Rs. 122.80 respectively. So far 5096 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 161.65 on 06-Jan-2014 and a 52 week low of Rs. 55.05 on 31-Jul-2013.

Last one week high and low of the scrip stood at Rs. 126.00 and Rs. 114.60 respectively. The current market cap of the company is Rs. 1137.60 crore.

The promoters holding in the company stood at 59.22% while Institutions and Non-Institutions held 16.65% and 24.13% respectively.

Indoco Remedies has received Certificate of Good Manufacturing Practice (GMP) Compliance from State Institute for Drug Control (SUKL), Czech Republic. The company received GMP Compliance for their Goa Plant II located at Verna Industrial Estate, Goa. The certificate pertains to manufacture of Sterile Ophthalmic Formulations.

The GMP certificate confirms that the plant fulfills the GMP recommendation of World Health Organization (WHO). The plant has been inspected in connection with marketing authorization(s) listing manufacturers located outside of the European Economic Area.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Indoco Remedies Share Price

219.40 -8.80 (-3.86%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×